The Union Health Ministry has amended Schedule Y of the Drugs and Cosmetics Rules, 1945, which states that animals will be spared the cruel tests for new drug registrations where complete data from similar toxicity experiments already exists for drugs approved abroad.
"Where the data on animal toxicity... Has been submitted and the same has been considered by the regulatory authority of the country which had earlier approved the drug, the animal toxicity studies shall not be required to be conducted in India except in cases where there are specific concerns recorded in writing," said a notification signed by the ministry's joint secretary, KL Sharma.
Explaining the amendment, a senior PETA official said if a particular drug, which is being introduced in India, has been approved in a particular country after tests on animals, then conducting such tests again for the same drug here will not be required.
The notification says that no permission will be required to conduct clinical trial intended for academic purposes in respect of approved drug formulation for "any new indication or new route of administration or new dose or new dosage form where the trial is approved by the Ethics Committee and subject to the provisions of sub-rule 5, the data generated is not intended for submission to licensing authority".
(REOPENS DEL66)
PETA said that last year, upon reviewing the requests from PETA and Maneka Gandhi, the Indian Investigational New Drugs Division recommended to the Drug Technical Advisory Board (DTAB) that animals be spared cruel tests for new drug registrations when complete data from earlier toxicity experiments already exist for drugs approved abroad.
PETA supporter and X-Files star Gillian Anderson, who was in India for a movie, had also written to the Union Health Minister requesting a ban on repeat experiments on animals in toxicity tests by amending the Drugs and Cosmetics Rules, 1945, PETA said.
"We look forward to continuing our association with the ministry to ensure that use of validated alternatives is encouraged as the Drug Technical Advisory Board has recommended," said Gauri Maulekhi, Humane Society International, India consultant.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
